Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

Core Insights - VolitionRx Limited announced a clinical study published in the Shock Journal, demonstrating elevated nucleosome levels in trauma patients, particularly those who develop complications [1][3]. Group 1: Study Findings - The study analyzed 674 trauma patients, revealing that levels of H3.1 and H3R8 Citrulline nucleosomes are significantly elevated shortly after traumatic injury, especially in patients who develop Venous Thromboembolism (VTE) [3]. - The findings highlight the potential of these nucleosomes as biomarkers for early risk identification and targeted preventive strategies in trauma care [3]. Group 2: Clinical Implications - The identification of reliable biomarkers in trauma patients is a critical clinical challenge, indicating an unmet need in emergency and surgical settings [2]. - The study's results support the commercialization efforts of Volition's Nu.Q® NETs product, which could aid clinicians in anticipating disease and guiding treatment decisions [4][5]. Group 3: Company Overview - Volition is a multinational company focused on advancing epigenetics, dedicated to improving outcomes for patients through earlier detection and monitoring of diseases [6][7]. - The company is developing cost-effective blood tests to detect and monitor various diseases, including cancers and conditions associated with NETosis, such as sepsis [7].